Inovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $13.00 at Oppenheimer

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective reduced by investment analysts at Oppenheimer from $15.00 to $13.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the company. StockNews.com cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 19th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.75.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.95 on Wednesday. The business has a fifty day moving average price of $1.80 and a 200 day moving average price of $2.53. Inovio Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $13.44. The stock has a market capitalization of $71.51 million, a P/E ratio of -0.49 and a beta of 1.40.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.23. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.01 million. As a group, equities research analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Nomura Holdings Inc. purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $28,000. Freedom Investment Management Inc. purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $31,000. Nuveen LLC purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $168,000. Charles Schwab Investment Management Inc. raised its stake in shares of Inovio Pharmaceuticals by 38.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 27,429 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Inovio Pharmaceuticals by 26.7% in the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 13,939 shares during the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.